Aurinia Pharmaceuticals (AUPH) Cash & Equivalents (2016 - 2026)

Aurinia Pharmaceuticals has reported Cash & Equivalents for 11 years, with the latest figure at $41.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 38.27% year-over-year to $41.0 million; the trailing twelve-month figure through Mar 2026 stood at $41.0 million (down 38.27% YoY), and the FY2025 full-year result was $80.2 million, down 3.86% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $41.0 million, down from $80.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $151.6 million in Q2 2022, with the low at $33.4 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $74.3 million across 5 years, with a median of $73.2 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 59.39% — and 2025, when it jumped 97.05%.
• Aurinia Pharmaceuticals' Cash & Equivalents stood at $94.2 million in 2022, then slumped by 48.1% to $48.9 million in 2023, then surged by 70.71% to $83.4 million in 2024, then declined by 3.86% to $80.2 million in 2025, then sank by 48.88% to $41.0 million in 2026.
• The last three Cash & Equivalents figures came in at $41.0 million (Q1 2026), $80.2 million (Q4 2025), and $73.2 million (Q3 2025), per Business Quant data.